A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of LY2127399 in Patients with Rheumatoid Arthritis (RA)

• Conditions: Rheumatoid Arthritis; MedDRA version: 12.1Level: LLTClassification code 10039073Term: Rheumatoid arthritis

• Registration Number: EUCTR2010-022208-36-LT
• Lead Sponsor: Eli Lilly and Company

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2010-12-28
• Last Update Posted: 17 March 2014

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 1505

Inclusion Criteria

• Completion of 24 weeks of participation in Study H9B-MC-BCDO or Study H9B-MC-BCDV, or have completed 100 weeks of participation in Study H9B-MC-BCDM
• Woman must not be pregnant, breastfeeding, or become pregnant during the study

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

• Current symptoms of a serious disorder or illness

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified